Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that a new indication application (the "Application") for the Company's trophoblast cell-surface antigen 2 (TROP2)-directed ...

The Zacks Medical - Dental Supplies industry in the Medical sector is seeing a robust demand for services since the beginning of this year, driven by patient preferences for timely and convenient care ...

French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for $9.5 billion, sending shares of the ...

Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments ...

Biotech stocks lagged the broader market in 2023 and 2024, and the SDPR S&P Biotech ETF (NYSE: XBI) is trading at the same level as in 2017. While biotech stocks soared during the COVID-19 ...

Pipeline and key clinical candidates for these companies: Galmed is a clinical stage biopharmaceutical company focused on the development of Aramchol for liver and fibro-inflammatory diseases.

CapsoVision, Inc.'s IPO exhibits high risks with slowing revenue growth, rising losses, and excessive valuation. Learn why a ...

On May 8, Michael Yee, Senior Biotech Analyst at Jefferies ... However, the takeaway is that many of these stocks are down more than 20-30% and, in fact, are trading at a decade-low P/E multiple.

The most recent analyst rating on (KRYS) stock is a Buy with a $208.00 price target. To see the full list of analyst forecasts on Krystal Biotech stock, see the KRYS Stock Forecast page.